TBIO stock forecast
Our latest prediction for Translate Bio Inc's stock price was made on the June 30, 2020 when the stock price was at 17.92$.
In the short term (2weeks), TBIO's stock price should underperform the market by -2.96%. During that period the price should oscillate between -12.56% and +11.44%.
In the medium term (3months), TBIO's stock price should underperform the market by -7.99%. During that period the price should oscillate between -40.74% and +26.45%.Get email alerts
Create a solid portfolio with TBIO
About Translate Bio Inc
Translate Bio is a clinical-stage mRNA therapeutics company developing a new class of potentially transformative medicines to treat diseases caused by protein or gene dysfunction, or to prevent infectious diseases by generating protective immunity. Translate Bio is primarily focused on applying its technology to treat pulmonary diseases with a lead pulmonary candidate being evaluated as an inhaled treatment for cystic fibrosis (CF) in a Phase 1/2 clinical trial. Additional pulmonary diseases are being evaluated in discovery-stage research programs that utilize a proprietary lung delivery platform. Translate Bio also believes its technology may apply broadly to a wide range of diseases, including diseases that affect the liver. Additionally, the platform may be applied to various classes of treatments, such as therapeutic antibodies or protein degradation. Translate Bio is also pursuing the development of mRNA vaccines for infectious diseases under a collaboration with Sanofi Pasteur.
At the moment the company generates 11M USD in revenues.
On its last earning announcement, the company reported a loss of -1.70$ per share.
The book value per share is 2.27$
Three months stock forecastJune 30, 2020
|Revenue USD||Gross Margin||Operating Income||Operating Margin||Net Income||Earnings Per Share||Dividends||Payout Ratio||Shares||Book Value Per Share||Operating Cash Flow||Cap Spending||Free Cash Flow|